These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 25255915)

  • 1. Is there an MCI reversion to cognitively normal? Analysis of Alzheimer's disease biomarkers profiles.
    Park MH; Han C
    Int Psychogeriatr; 2015 Mar; 27(3):429-37. PubMed ID: 25255915
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Varying strength of cognitive markers and biomarkers to predict conversion and cognitive decline in an early-stage-enriched mild cognitive impairment sample.
    Egli SC; Hirni DI; Taylor KI; Berres M; Regeniter A; Gass A; Monsch AU; Sollberger M
    J Alzheimers Dis; 2015; 44(2):625-33. PubMed ID: 25322924
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Artificially low mild cognitive impairment to normal reversion rate in the Alzheimer's Disease Neuroimaging Initiative.
    Thomas KR; Eppig JS; Weigand AJ; Edmonds EC; Wong CG; Jak AJ; Delano-Wood L; Galasko DR; Salmon DP; Edland SD; Bondi MW;
    Alzheimers Dement; 2019 Apr; 15(4):561-569. PubMed ID: 30610833
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cerebrospinal fluid cortisol and clinical disease progression in MCI and dementia of Alzheimer's type.
    Popp J; Wolfsgruber S; Heuser I; Peters O; Hüll M; Schröder J; Möller HJ; Lewczuk P; Schneider A; Jahn H; Luckhaus C; Perneczky R; Frölich L; Wagner M; Maier W; Wiltfang J; Kornhuber J; Jessen F
    Neurobiol Aging; 2015 Feb; 36(2):601-7. PubMed ID: 25435336
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neuronal injury biomarkers and prognosis in ADNI subjects with normal cognition.
    Toledo JB; Weiner MW; Wolk DA; Da X; Chen K; Arnold SE; Jagust W; Jack C; Reiman EM; Davatzikos C; Shaw LM; Trojanowski JQ;
    Acta Neuropathol Commun; 2014 Mar; 2():26. PubMed ID: 24602322
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic classification of mild cognitive impairment and Alzheimer's disease: MRI independent component analysis.
    Willette AA; Calhoun VD; Egan JM; Kapogiannis D;
    Psychiatry Res; 2014 Nov; 224(2):81-8. PubMed ID: 25194437
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Head Turning Sign in Dementia and Mild Cognitive Impairment: Its Relationship to Cognition, Behavior, and Cerebrospinal Fluid Biomarkers.
    Durães J; Tábuas-Pereira M; Araújo R; Duro D; Baldeiras I; Santiago B; Santana I
    Dement Geriatr Cogn Disord; 2018; 46(1-2):42-49. PubMed ID: 30092564
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neuropsychological criteria for mild cognitive impairment improves diagnostic precision, biomarker associations, and progression rates.
    Bondi MW; Edmonds EC; Jak AJ; Clark LR; Delano-Wood L; McDonald CR; Nation DA; Libon DJ; Au R; Galasko D; Salmon DP
    J Alzheimers Dis; 2014; 42(1):275-89. PubMed ID: 24844687
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Performance of aβ1-40, aβ1-42, total tau, and phosphorylated tau as predictors of dementia in a cohort of patients with mild cognitive impairment.
    Parnetti L; Chiasserini D; Eusebi P; Giannandrea D; Bellomo G; De Carlo C; Padiglioni C; Mastrocola S; Lisetti V; Calabresi P
    J Alzheimers Dis; 2012; 29(1):229-38. PubMed ID: 22232006
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Injury markers but not amyloid markers are associated with rapid progression from mild cognitive impairment to dementia in Alzheimer's disease.
    van Rossum IA; Visser PJ; Knol DL; van der Flier WM; Teunissen CE; Barkhof F; Blankenstein MA; Scheltens P
    J Alzheimers Dis; 2012; 29(2):319-27. PubMed ID: 22233766
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The association between biomarkers in cerebrospinal fluid and structural changes in the brain in patients with Alzheimer's disease.
    Li X; Li TQ; Andreasen N; Wiberg MK; Westman E; Wahlund LO
    J Intern Med; 2014 Apr; 275(4):418-27. PubMed ID: 24237038
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Data-Driven vs Consensus Diagnosis of MCI: Enhanced Sensitivity for Detection of Clinical, Biomarker, and Neuropathologic Outcomes.
    Edmonds EC; Smirnov DS; Thomas KR; Graves LV; Bangen KJ; Delano-Wood L; Galasko DR; Salmon DP; Bondi MW
    Neurology; 2021 Sep; 97(13):e1288-e1299. PubMed ID: 34376506
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Use of cerebrospinal fluid (CSF) biomarkers for Alzheimer's type dementia: diagnosis in mild cognitive impairment].
    Verhey FR; Visser PJ
    Ned Tijdschr Geneeskd; 2013; 157(11):A5596. PubMed ID: 23484512
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cognition, brain atrophy, and cerebrospinal fluid biomarkers changes from preclinical to dementia stage of Alzheimer's disease and the influence of apolipoprotein e.
    Susanto TA; Pua EP; Zhou J;
    J Alzheimers Dis; 2015; 45(1):253-68. PubMed ID: 25524955
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Integrating Biomarkers for Underlying Alzheimer's Disease in Mild Cognitive Impairment in Daily Practice: Comparison of a Clinical Decision Support System with Individual Biomarkers.
    Rhodius-Meester HF; Koikkalainen J; Mattila J; Teunissen CE; Barkhof F; Lemstra AW; Scheltens P; Lötjönen J; van der Flier WM
    J Alzheimers Dis; 2016; 50(1):261-70. PubMed ID: 26577521
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Test sequence of CSF and MRI biomarkers for prediction of AD in subjects with MCI.
    Vos S; van Rossum I; Burns L; Knol D; Scheltens P; Soininen H; Wahlund LO; Hampel H; Tsolaki M; Minthon L; Handels R; L'Italien G; van der Flier W; Aalten P; Teunissen C; Barkhof F; Blennow K; Wolz R; Rueckert D; Verhey F; Visser PJ
    Neurobiol Aging; 2012 Oct; 33(10):2272-81. PubMed ID: 22264648
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multimodal prediction of dementia with up to 10 years follow up: the Gothenburg MCI study.
    Eckerström C; Olsson E; Klasson N; Berge J; Nordlund A; Bjerke M; Wallin A
    J Alzheimers Dis; 2015; 44(1):205-14. PubMed ID: 25201779
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cerebrospinal fluid tau protein and periventricular white matter lesions in patients with mild cognitive impairment: implications for 2 major pathways.
    Maruyama M; Matsui T; Tanji H; Nemoto M; Tomita N; Ootsuki M; Arai H; Sasaki H
    Arch Neurol; 2004 May; 61(5):716-20. PubMed ID: 15148149
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The new 2011 recommendations of the National Institute on Aging and the Alzheimer's Association on diagnostic guidelines for Alzheimer's disease: Preclinal stages, mild cognitive impairment, and dementia].
    Croisile B; Auriacombe S; Etcharry-Bouyx F; Vercelletto M; ;
    Rev Neurol (Paris); 2012 Jun; 168(6-7):471-82. PubMed ID: 22579080
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of the use of biomarkers in cerebrospinal fluid for Alzheimer's disease.
    Valcárcel-Nazco C; Perestelo-Pérez L; Molinuevo JL; Mar J; Castilla I; Serrano-Aguilar P
    J Alzheimers Dis; 2014; 42(3):777-88. PubMed ID: 24916543
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.